LRIG3 Antibody (814834) [Alexa Fluor® 488]

• Applications: Flow
• Clone: 814834
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488
• Concentration: Please see the vial label for concentration. If unlisted please contact technical services.

LRIG3 Antibody (814834) [Alexa Fluor® 488] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human LRIG3
  Asp28-Thr807
  Accession # Q6UXM1
• Specificity: Detects human LRIG3 in direct ELISAs and Western blots. Detects mouse LRIG3 in Western blots. Mouse LRIG3 detection in Flow Cytometry was not tested. In direct ELISAs, no cross-reactivity with recombinant human LRIG1 is observed.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: LRIG3
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Application Notes: Flow Cytometry: Please use 0.25-1 ug of conjugated antibody per 10e6 cells.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
• Preservative: 0.09% Sodium Azide
• Concentration: Please see the vial label for concentration. If unlisted please contact technical services.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

LRIG3 (leucine-rich repeats and Ig-like domains-3) is an approximately 140-170 kDa type I transmembrane glycoprotein member of the mammalian LRIG glycoprotein family. This family contains three members who share 45 - 50% amino acid (aa) identity (1). All members contain at least fifteen LRRs, accompanied by two flanking cysteine-rich regions, and three C2-type Ig-like domains in their extracellular domains (ECD) (1). LRIG3 mRNA is widely expressed, with highest levels in stomach, skin, thyroid and small intestine (1). Human LRIG3 is synthesized as a 1120 amino acid (aa) precursor. It contains a 24 aa signal sequence, a 786 aa ECD, a 21 aa transmembrane sequence, and a 289 aa intracellular region. One splice variant exists that has a 19 aa substitution for the first 79 aa of the standard (or long) form. This substitution appears to encode an alternate signal sequence, resulting in a mature protein that lacks the first and part of the second LRR. LRIG1, a related family member, is known to bind the EGF family receptors ErbB1-4, via either its LRR or Ig-like domains. It also binds the ubiquitin ligase, c-Cbl, and promotes ubiquitination, internalization and destruction of these receptors (2, 3). It is not known whether LRIG3 performs similar functions. Within the cell, LRIG3 is expressed in the perinuclear region as well as on the cell surface. Perinuclear location of LRIG3 in grade III and IV astrocytic tumors has been associated with better patient survival (4). Human LRIG3 ECD shares 91%, 92%, 95% and 98% aa sequence identity with mouse, rat, bovine and canine LRIG3 ECD, respectively.

1. Guo, D. et al. (2004) Genomics 84:157.
2. Gur, G. et al. (2004) EMBO J. 23:3270.
3. Laederich, M.B. (2004) J. Biol. Chem. 279:47050.
4. Guo, D. et al. (2006) Acta Neuropathol. (Berl.) 111:238.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: LRIG3